Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00900614
Recruitment Status : Completed
First Posted : May 13, 2009
Last Update Posted : July 31, 2019
Sponsor:
Information provided by (Responsible Party):
Aprea Therapeutics

Brief Summary:
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.

Condition or disease Intervention/treatment Phase
Hematologic Neoplasms Prostatic Neoplasms Drug: APR-246 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma
Study Start Date : May 2009
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer


Intervention Details:
  • Drug: APR-246
    Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.


Primary Outcome Measures :
  1. Dose-Limiting Toxicity (DLT) is reached and HFD is defined accordingly, OR the dose, which is expected to result in maximum plasma concentration close to, but not exceeding 35 μg/ml in any single patient without showing signs of DLT. [ Time Frame: 21 days ]

Secondary Outcome Measures :
  1. Determination of the toxicity and safety profile of APR-246 based on safety parameters from the entire study period. [ Time Frame: continuously during 21 days ]
  2. Determination of the PK profile for up to 22 hours after the last APR-246 infusion. Cmax (maximal plasma concentration), AUC (area under the curve), t1/2 (half-life) and clearance will be determined. [ Time Frame: continuously, during 21 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Summary criteria for participant selection:

Inclusion Criteria:

  • Male or female ≥ 18 years of age.
  • Any below mentioned advanced disease, which is not eligible for other therapies. The diagnosis should have been confirmed either histologically or cytologically:

    1. Acute myeloid leukemia.
    2. Acute lymphoid leukemia.
    3. Chronic lymphocytic leukemia.
    4. Chronic myeloid leukemia.
    5. Chronic myelomonocytic leukemia.
    6. Multiple myeloma.
    7. Non Hodgkin's lymphoma.
    8. Hodgkin's lymphoma.
    9. Myelodysplastic syndrome.
    10. Myelofibrosis.
    11. Hormone refractory, metastatic prostate carcinoma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900614


Locations
Layout table for location information
Sweden
Section of Haematology and Coagulation, Sahlgrenska University Hospital
Göteborg, Sweden, 41345
Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge
Stockholm, Sweden, SE 141 86
Clinical Research and Development Unit, Department of Oncology, Akademiska Hospital
Uppsala, Sweden, 75185
Department of Haematology, Akademiska Hospital
Uppsala, Sweden, 75185
Department of Hematology, University Hospital
Örebro, Sweden, 70185
Urology clinic, University Hospital
Örebro, Sweden, 70185
Sponsors and Collaborators
Aprea Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Sören Lehmann, MD, PhD Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, SE-141 86, Stockholm, Sweden
Layout table for additonal information
Responsible Party: Aprea Therapeutics
ClinicalTrials.gov Identifier: NCT00900614    
Other Study ID Numbers: APR-246-01
First Posted: May 13, 2009    Key Record Dates
Last Update Posted: July 31, 2019
Last Verified: July 2019
Keywords provided by Aprea Therapeutics:
Hematologic malignancy
Prostate carcinoma
Hematologic cancer
Prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Prostatic Neoplasms
Hematologic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Hematologic Diseases